Mechanisms of resistance to immune checkpoint inhibitors

DSpace/Manakin Repository

Mechanisms of resistance to immune checkpoint inhibitors

Citable link to this page

 

 
Title: Mechanisms of resistance to immune checkpoint inhibitors
Author: Jenkins, Russell W; Barbie, David A; Flaherty, Keith T

Note: Order does not necessarily reflect citation order of authors.

Citation: Jenkins, Russell W, David A Barbie, and Keith T Flaherty. 2018. “Mechanisms of resistance to immune checkpoint inhibitors.” British Journal of Cancer 118 (1): 9-16. doi:10.1038/bjc.2017.434. http://dx.doi.org/10.1038/bjc.2017.434.
Full Text & Related Files:
Abstract: Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors (‘targeted therapies’) largely act on cancer cells directly, immune checkpoint inhibitors reinvigorate anti-tumour immune responses by disrupting co-inhibitory T-cell signalling. While resistance routinely develops in patients treated with conventional cancer therapies and targeted therapies, durable responses suggestive of long-lasting immunologic memory are commonly seen in large subsets of patients treated with ICI. However, initial response appears to be a binary event, with most non-responders to single-agent ICI therapy progressing at a rate consistent with the natural history of disease. In addition, late relapses are now emerging with longer follow-up of clinical trial populations, suggesting the emergence of acquired resistance. As robust biomarkers to predict clinical response and/or resistance remain elusive, the mechanisms underlying innate (primary) and acquired (secondary) resistance are largely inferred from pre-clinical studies and correlative clinical data. Improved understanding of molecular and immunologic mechanisms of ICI response (and resistance) may not only identify novel predictive and/or prognostic biomarkers, but also ultimately guide optimal combination/sequencing of ICI therapy in the clinic. Here we review the emerging clinical and pre-clinical data identifying novel mechanisms of innate and acquired resistance to immune checkpoint inhibition.
Published Version: doi:10.1038/bjc.2017.434
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765236/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34868911
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters